Image source: NIH Image Gallery via Flickr. It’s been a year to forget for MannKind (NASDAQ:MNKD) shareholders, and it may be about to get worse. Last year everything appeared to be going MannKind’s way. Afrezza, the company’s fast-acting inhaled diabetes drug, was approved by the Food and Drug Administration, and it landed an experienced licensing […]
Read More